Shire Sets Sights on Dry Eye Disease with Deal for Parion Drug

by | May 1, 2017 | Business Enhancements

Shire is paying $20 million up front to acquire rights to a drug that Parion Sciences has developed as a potential treatment for dry eye disease. The deal calls for Shire (NASDAQ: SHPG) to take the lead on further work on P-321, a compound that Durham, NC-based Parion has tested in early-stage clinical trials. If […]

Executive Relationship Marketing: The ‘Secret Sauce’ for any successful early-stage company

 Imagine what your company’s revenue would look like if you could arrange 10-15 meetings in 90 days with top C-Suite executives. This White Paper goes into depth on this sophisticated process.

Your White Paper is on its way!